American Journal of Cardiology
Volume 102, Issue 9, Supplement , Pages 1J-3J , 3 November 2008

Introduction

  • David G. Rizik, MD

      Affiliations

    • Corresponding Author InformationAddress for reprints: David G. Rizik, MD, Scottsdale Healthcare Hospitals, Suite A 100, 9755 North 90th Street, Scottsdale, Arizona 85258

References 

  1. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521
  2. Camenzind E, Nordman AJ, Briel M, Bucher HC. Safety of drug-eluting stents: insights from meta-analysis. Presented at the European Society of Cardiology Annual Congress; September 2–6 2006;Barcelona, Spain. Hotline I; 707009
  3. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  4. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030–1039
  5. Stettler C, Wandel S, Allemann S, Kastrati A, Morice M, Schömig A, et al Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948
  6. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  7. James S, Carlsson J, Lindback J, Nilsson T, Stenestrand U, Wallentin L, et al. Long term mortality after drug eluting stents in Sweden: an additional year of follow-up. Presented at the European Society of Cardiology Annual Congress; September 1–5 2007;Vienna, Austria
  8. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923–2932
  9. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–198
  10. Bonello L. Platelet monitoring of clopidogrel response using VASP phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. Presented at the American College of Cardiology Scientific Sessions/i2 Summit–Society for Cardiovascular Angiography and Interventions Annual Meeting; Chicago, Illinois; March 29 2008;

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9149(08)01491-4

doi: 10.1016/j.amjcard.2008.09.002

American Journal of Cardiology
Volume 102, Issue 9, Supplement , Pages 1J-3J , 3 November 2008

Article Tools